Trials / Not Yet Recruiting
Not Yet RecruitingNCT07446101
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Administered SC |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2026-03-03
- Last updated
- 2026-03-19
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07446101. Inclusion in this directory is not an endorsement.